Glenmark Pharma USA to Launch Micafungin Injection

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Glenmark Pharmaceuticals Inc., USA is set to launch Micafungin for Injection USP, available in 50 mg/vial and 100 mg/vial (Single-Dose Vial) formulations. The company will begin distribution in September 2025.

Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to Mycamine® for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA-021506.

According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million.

Marc Kikuchi, President & Business Head, North America, commented, "We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need."

Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with a presence across Branded, Generics, and OTC segments, focusing on respiratory, dermatology, and oncology. The company has 11 manufacturing facilities across 4 continents and operations in over 80 countries. Glenmark is ranked among the Top 100 Companies by R&D and Pharmaceutical Sales, 2022, by In Vivo/Scrip 100 and in the Top 50 Generics and Biosimilars Companies by Sales, 2022, by Generics Bulletin/In Vivo.

Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi). The organization has impacted over 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com.